On January 11, 2021, leading experts in cancer immunotherapy presented an overview of the recently published "The Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Acute Leukemia" during a live webinar.
Webinar Faculty:
The webinar discussed:
Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.
This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.Please note that the on-demand webinar is not available for continuing education credits#Leukemia #AntibodyDrugConjugates #BispecificAntibodies #Blinatumomab #Tisagenlecleucel #PresentationSlides #RecordedWebinar #Clinician #NursePractitioner #Oncologist #PatientAdvocate #Pharmacist #RegisteredNurse #PhysicianAssistant #ClinicalPracticeGuideline #2021
Meeting: SITC Clinical Practice Guideline Webinar – Immunotherapy for the Treatment of Acute Leukemia; Faculty: Michael M. Boyiadzis, MD, MHSc – University of Pittsburgh; Renier J. Brentjens, MD, PhD – Memorial Sloan-Kettering Cancer Center; Jorge M. Cortes, MD – Georgia Cancer Center; Mark R. Litzow, MD – Mayo Clinic Cancer Center; Date: January 11, 202101:01:29